These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy. Qin Y; Li S; Li XJ; Yang S Neurosci Bull; 2022 Nov; 38(11):1397-1408. PubMed ID: 35608753 [TBL] [Abstract][Full Text] [Related]
8. Nucleic Acid Therapeutics in Huntington's Disease. Singh K; Roy I Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088 [TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease. Alkanli SS; Alkanli N; Ay A; Albeniz I Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283 [TBL] [Abstract][Full Text] [Related]
10. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802 [TBL] [Abstract][Full Text] [Related]
11. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models. Morelli KH; Wu Q; Gosztyla ML; Liu H; Yao M; Zhang C; Chen J; Marina RJ; Lee K; Jones KL; Huang MY; Li A; Smith-Geater C; Thompson LM; Duan W; Yeo GW Nat Neurosci; 2023 Jan; 26(1):27-38. PubMed ID: 36510111 [TBL] [Abstract][Full Text] [Related]
12. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease. Choi DE; Shin JW; Zeng S; Hong EP; Jang JH; Loupe JM; Wheeler VC; Stutzman HE; Kleinstiver B; Lee JM Elife; 2024 Jun; 12():. PubMed ID: 38869243 [TBL] [Abstract][Full Text] [Related]
15. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease. Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975 [TBL] [Abstract][Full Text] [Related]
16. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology. Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692 [TBL] [Abstract][Full Text] [Related]
17. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model. Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561 [TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease. Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337 [TBL] [Abstract][Full Text] [Related]
20. Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies. Tong H; Yang T; Xu S; Li X; Liu L; Zhou G; Yang S; Yin S; Li XJ; Li S Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]